+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
540395 CHEMCRUX

Chemcrux Enterprises Share Price

 

 

Chemcrux Enterprises live price: ₹88.17. It opened at ₹86 vs previous close ₹88; intraday high/low: ₹89/₹86. The 50 & 200 DMA stand at ₹89.56/₹101.64.

Chemcrux Enterprises Performance

  • Today's Low
  • ₹86
  • Today's High
  • ₹89
  • 52 Week Low
  • ₹64
  • 52 Week High
  • ₹159
  • Open Price₹86
  • Previous Close₹88
  • Volume3,018
  • 50 DMA₹89.56
  • 100 DMA₹92.08
  • 200 DMA₹101.64

Chemcrux Enterprises Chart

Investment Returns

  • Over 1 Month -1.22%
  • Over 3 Month + 12.2%
  • Over 6 Month -14.93%
  • Over 1 Year -32.59%

Smart Investing Starts Here Start SIP with Chemcrux Enterprises for Steady Growth!

Invest Now

Chemcrux Enterprises Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 35
  • PEG Ratio
  • -7.4
  • Market Cap Cr
  • 131
  • P/B Ratio
  • 1.7
  • Average True Range
  • 3.23
  • EPS
  • -
  • Dividend Yield
  • 1.1
  • MACD Signal
  • -0.46
  • RSI
  • 43.09
  • MFI
  • 27.86

Chemcrux Enterprises Financials

Chemcrux Enterprises Technicals

EMA & SMA

Current Price
₹88.17
+ 0.24 (0.27%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹88.90
  • 50 Day
  • ₹89.60
  • 100 Day
  • ₹92.10
  • 200 Day
  • ₹101.60

Resistance and Support

87.36 Pivot Speed
  • R3 91.68
  • R2 90.34
  • R1 88.70
  • S1 85.72
  • S2 84.38
  • S3 82.74

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Chemcrux Enterprises has an operating revenue of Rs. 80.65 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 7% is okay, ROE of 4% is fair but needs improvement. The company has a reasonable debt to equity of 28%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 61 which is a FAIR score but needs to improve its earnings, a RS Rating of 40 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 37 indicates it belongs to a strong industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Chemcrux Enterprises Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-14 Audited Results & Final Dividend
2026-02-05 Quarterly Results
2025-11-06 Quarterly Results
2025-08-06 Quarterly Results & ESOP
2025-05-20 Audited Results & Final Dividend
Date Purpose Remarks
2025-09-17 FINAL Rs.1.00 per share(10%)Final Dividend
2024-09-06 FINAL Rs.1.00 per share(10%)Final Dividend
2023-09-05 FINAL Rs.2.00 per share(20%)Final Dividend
2022-09-16 FINAL Rs.2.00 per share(20%)Final Dividend
View Chemcrux Enterprises Dividend History Arrow
Date Purpose Remarks
2021-09-07 Bonus Rs.0.00 issue of equity shares of in the ratio of 2:1 of Rs. 10/-.

Chemcrux Enterprises Shareholding Pattern

72.92%
25.84%
1.24%

Chemcrux Enterprises FAQs

Chemcrux Enterprises share price is ₹88 As on 10 July, 2026 | 05:35

The Market Cap of Chemcrux Enterprises is ₹130.6 Cr As on 10 July, 2026 | 05:35

The P/E ratio of Chemcrux Enterprises is 35 As on 10 July, 2026 | 05:35

The PB ratio of Chemcrux Enterprises is 1.7 As on 10 July, 2026 | 05:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23